PACAP/VIP Monoclonal Antibodies

Fulcrum Agrees to Merge With Slate Medicines, Plans Nasdaq Relaunch as SLTE

The merger shifts Fulcrum's remaining capital into Slate's PACAP-targeting migraine program with financing sized to fund development into 2029